SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Biotech Bash - Recs and Wrecks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ryan Weisman who wrote (162)9/29/1997 9:21:00 AM
From: Henry Niman   of 171
 
LGND just came out with postive clinicals for ORAL, Targretin Phase II/III
data for CTCL (at the higher dose all patients responded). Numbers are still on the
small side, but 100% is a pretty impressive number (improvement ranged from
stabilization of the disease to complete remission). CTCL NDA for ORAL as well as
topical projected for 2nd half of next year. Trial is International and VERY significant
because ORAL Targretin is what would be prescribed off-label for Type II diabetes.
Wires are starting to heat up!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News